Regen BioPharma to Acquire 03 Life Sciences

TL;DR

Regen BioPharma is buying 03 Life Sciences to boost its drug pipeline. Deal expected Q4 2024.

AI Summary

Regen BioPharma Inc. announced on September 18, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of 03 Life Sciences, a company focused on developing novel therapeutic antibodies. The acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This strategic move aims to expand Regen BioPharma's pipeline and leverage 03 Life Sciences' expertise in antibody development.

Why It Matters

This acquisition could significantly bolster Regen BioPharma's therapeutic pipeline by integrating 03 Life Sciences' antibody development capabilities, potentially leading to new drug candidates.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and the possibility that the acquired company's technology may not perform as expected.

Key Players & Entities

• Regen BioPharma Inc. (company) — Acquiring company
• 03 Life Sciences (company) — Acquired company
• September 18, 2024 (date) — Announcement date
• fourth quarter of 2024 (date) — Expected closing period

FAQ

Filing Documents

• form8-k.htm (8-K) — 30KB
• 0001493152-24-037011.txt ( ) — 197KB
• rgbp-20240918.xsd (EX-101.SCH) — 3KB
• rgbp-20240918_lab.xml (EX-101.LAB) — 33KB
• rgbp-20240918_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 REGEN BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Nevada 45-5192997 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Commission File No. 333-191725 4700 Spring Street , St 304 , La Mesa , California 91942 (Address of Principal Executive Offices) (619) 722 5505 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On September 18, 2024 the Board of Directors of Regen Biopharma, Inc.("Regen") declared a dividend to all shareholders of record as of October 17,2024 ("Record Date") to be paid to shareholders on or about November 1, 2024 such dividend to be payable in shares of the Regen's authorized but unissued Common Stock and to consist of one share of Common Stock for every one share of Regen Biopharma, Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGEN BIOPHARMA, INC. Dated: September 18, 2024 By: /s/ David Koos

View Full Filing

View this 8-K filing on SEC EDGAR